BY MIRABEL ODETA
Purdue Pharma announced on Friday that it has officially завершed its bankruptcy process and ceased operating in its former corporate structure, re-emerging as a nonprofit organization dedicated to combating opioid addiction. The newly formed entity, Knoa Pharma, will now focus entirely on addressing the damage caused by the opioid crisis in the United States.
The transition marks the culmination of a long and controversial legal battle that began when Purdue filed for Chapter 11 bankruptcy in 2019. As part of a sweeping $7.4 billion settlement, the company committed all of its resources to supporting addiction treatment, prevention, and recovery efforts. The restructuring plan was designed to transform the company from a profit-driven pharmaceutical manufacturer into a public health-oriented organization.
Purdue had faced thousands of lawsuits over its role in fueling the U.S. opioid epidemic, largely tied to its aggressive marketing of the powerful painkiller OxyContin. Over the years, the company admitted to multiple instances of misconduct, including misleading regulators and healthcare providers about the drug’s addictive risks. It also acknowledged paying illegal kickbacks to doctors to increase prescriptions.
The company’s criminal sentencing earlier this week removed the final legal barrier to implementing its bankruptcy plan. This milestone officially allowed the restructuring to take effect, closing one chapter of Purdue’s history while opening another under a different mission.
Despite this transition, the outcome has left many victims of the opioid crisis dissatisfied. During court proceedings, individuals and families affected by addiction shared deeply personal accounts of loss and suffering. A significant number expressed frustration with the settlement process, particularly the difficulty of obtaining compensation. Reports indicate that roughly 40% of individual claims submitted by victims have already been denied, raising concerns about fairness and access to relief.
The leadership of Knoa Pharma reflects a shift toward public health expertise and accountability. Its board includes Rahul Gupta, who previously led the White House Office of National Drug Control Policy under Joe Biden; Paul Rothman, former CEO of Johns Hopkins University School of Medicine; and David Saltzman, co-founder of the Atria Health and Research Institute. Their combined experience is expected to guide the organization’s new direction and ensure a stronger emphasis on patient care and ethical practices.
Under its nonprofit model, Knoa Pharma has pledged to make overdose reversal medications and treatments for opioid use disorder widely accessible, offering them at or below the cost of production. This approach is intended to remove financial barriers and expand access to life-saving care, particularly in communities hardest hit by addiction.
A large portion of the settlement funds will be distributed to state and local governments that have borne the financial and social burden of the opioid epidemic. These funds are expected to support public health programs, treatment centers, and prevention initiatives. Additionally, $865 million has been allocated to individuals who suffered addiction or lost loved ones due to opioids, though the distribution process remains a point of contention.
The transformation of Purdue Pharma into a nonprofit entity represents a rare and significant shift in how a major corporation addresses the consequences of its actions. While the new structure aims to prioritize healing and accountability, ongoing concerns from victims highlight the complexity of delivering justice in the wake of a public health crisis that has affected millions.
Original article
Comments